AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$VIVS

Lialin Tony Serge purchased $3K of VIVS

Lialin Tony Serge (Chief Commercial Officer) purchased 10,000 shares of VivoSim Labs, INC. (VIVS) at $0.28 on 2026-08-31.

Original reporting
SEC EDGAR · Lialin Tony Serge
Published Sep 1, 2026, 8:01 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$VIVS
Neutral
high confidence
Mentioned
$VIVS
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$VIVSNeutralLow
01

Why it matters

The purchase is modest and unlikely to move the stock, but it confirms the officer's continued stake.

02

Market read

Minor insider purchase with limited trading relevance.

03

What to watch

Potential upcoming commercial contracts could make the purchase more meaningful.

Relevance 4/10Novelty 2/10Timing: filed Sep 1 2026

Background

Form 4 disclosures provide the first public record of insider trades.

Company-level read

Ticker impact

$VIVSNeutralHigh confidence
Context

CCO Lialin Tony Serge bought 10,000 shares at $0.2804, total $2,804 (Form 4 filing).

Expected impact

little to no movement; may slightly support price in short term.

Evidence & confidence

Purchase size is trivial relative to market cap; insider is not a major shareholder.

Market effects

Sector

None; transaction is company‑specific.

Regional

None; limited to VIVS shareholders.

Global

None

Counterpoint

What could challenge this read

Even small insider buys can signal confidence; monitor if more purchases follow.

Key entities

  • Company
    VivoSim Labs, Inc.

    Biotech company listed under ticker VIVS.

  • Insider
    Lialin Tony Serge

    Chief Commercial Officer of VivoSim Labs.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

VIVS insider trading history →

Related articles

OCT 7
$VIVSMed

FDA updates regulations to allow non-animal drug safety testing

The FDA updated regulations to allow non-animal methods for drug safety testing, replacing 'animal tests' with 'nonclinical tests'. VivoSim Labs (VIVS) offers 3D human cellular models for preclinical testing, aiming to reduce drug development costs by identifying toxic molecules early. The company's models use primary human cells and could help avoid costly failures in clinical trials.

investing.com2 min
OCT 7
$VIVSMed

VivoSim Labs Celebrates Updated FDA Regulations Allowing Greater use of Non-Animal Testing Methods

VivoSim Labs (VIVS) welcomes FDA's updated regulations allowing greater use of non-animal testing methods. The rule replaces 'animal tests' with 'nonclinical tests,' benefiting VivoSim's 3D human cellular models. VivoSim's models can identify drug safety risks earlier, reducing development costs. The company expects accelerated adoption of its NAM models following the FDA's roadmap.

globenewswire.com2 min
AUG 6
$VIVSMedAI 8/10

VivoSim Labs Regains Nasdaq Compliance, Boosts Cash to $10.1M and Projects 500%+ Revenue Growth for 2027 – Minichart

VivoSim Labs (Nasdaq: VIVS) said it regained Nasdaq compliance with Rule 5550(b)(1) by meeting the $2.5M stockholders’ equity requirement. The company reported cash of about $10.1M as of Aug. 3, 2026, after receiving $5M from Eli Lilly and $1M from escrow, and completing a July 17 financing raising $4M gross. It reiterated guidance for 2027 revenue growth of 500%+.

minichart.com.sg5 min
AUG 6
$VIVSMed

VivoSim Provides Financial and Listing Compliance Update

VivoSim Labs, INC. (VIVS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 VivoSim Provides Financial and Listing Compliance Update San Diego, CA — August 6, 2026 — VivoSim Labs, Inc. (Nasdaq: VIVS) (the “Company” or “VivoSim”), a provider of next-generation New Approach Methodologies (NAM) 3d human cellular models for preclinical safety, t

SEC EDGAR 8-K2 min
AUG 6
$VIVSMed

VivoSim reports 13.4M shares outstanding after July warrant exercises

VivoSim (Nasdaq: VIVS) said it regained Nasdaq Rule 5550(b)(1) compliance on Aug. 4, 2026 after meeting the $2.5 million minimum stockholders’ equity requirement. The company reported July cash inflows of $5.0 million milestone plus $1.0 million escrow release tied to an FXR program sale to Eli Lilly, and a July 17 financing raising $4.0 million gross ($3.6 million net). Shares rose from 3.19M (Jun 30) to 13.39M (Aug 3) after 9.90M warrant exercises; cash was about $10.1M as of Aug 3.

stocktitan.net4 min